EUVIMEDEUVIMED entdecken
Crossref

Designing superiority trials with window mean survival time as a primary endpoint

Mitchell Paukner iD, Richard Chappell

Statistics in Medicine · 2023

DOI: 10.1002/sim.9738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2023. Verfasst von Mitchell Paukner und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics, University of Wisconsin, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Research Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Merck KGaA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Window mean survival time (WMST), a simple extension of restricted mean survival time (RMST), allows for clinicians to evaluate the mean survival difference between treatment groups in specific windows of time during the follow‐up period of a trial. The advantages of WMST are numerous. Not only does it produce estimates of treatment effect that can be meaningfully interpreted, but also has power advantages over competing methods when hazards are non‐proportional (NPH). WMST, like RMST, is currently underutilized due to clinicians' lack of familiarity with tests comparing mean survival times and the lack of tools to facilitate trial design with this endpoint. The aim of this article is to provide investigators with insights and software to design trials with WMST as the primary endpoint. Functions for performing power and sample size calculations are provided in the survWMST package in R available on GitHub.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignHumansProportional Hazards ModelsSurvival RateSample SizeTime FactorsSurvival Analysis

Stichwörter der Autor:innen

logrank testnon-proportional hazardsrestricted mean survival timesurvival data

Autor:innen und Institutionen

  • Department of Statistics, University of Wisconsin, Madison, Wisconsin, USA.
  • Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin, USA.

ORCID-Profile: Mitchell Paukner

Förderung

  • Merck KGaA

Zitieren

APA

Paukner, M., & Chappell, R. (2023). Designing superiority trials with window mean survival time as a primary endpoint. Statistics in Medicine. https://doi.org/10.1002/sim.9738

Vancouver

Paukner M, Chappell R. Designing superiority trials with window mean survival time as a primary endpoint. Statistics in Medicine. 2023. doi:10.1002/sim.9738

BibTeX
@article{Paukner2023,
  author = {Paukner, Mitchell and Chappell, Richard},
  title = {Designing superiority trials with window mean survival time as a primary endpoint},
  journal = {Statistics in Medicine},
  year = {2023},
  doi = {10.1002/sim.9738}
}
Kostenlos starten →